The most important thing about the new sublingual minoxidil trial is not just that midfrontal hair counts improved. It is the mechanism: non-hormonal follicle growth support in people receiving full-dose testosterone therapy.
That is a big deal because many testosterone-treated transgender and gender-diverse people face a difficult trade-off. Testosterone can trigger androgenetic alopecia in genetically susceptible follicles, but the standard DHT-blocking drugs may feel psychologically or medically complicated for someone using testosterone for masculinization.
Sublingual minoxidil offers a different logic. It does not try to lower testosterone. It does not directly block DHT. Instead, it appears to push follicle biology toward stronger growth through minoxidil’s familiar but still not fully solved pathways: minoxidil sulfate activation, dermal papilla signaling, ATP-sensitive potassium channels, VEGF, vascular support, and anagen prolongation.
The Big Idea: Sublingual Minoxidil Is a Growth Signal, Not an Anti-Androgen
Pattern hair loss is often framed as a DHT problem, and that is partly true. DHT can act on genetically susceptible dermal papilla cells and push follicles toward miniaturization. But hair regrowth is not only about reducing the damaging signal. It is also about strengthening the growth signal.
Minoxidil belongs on the growth-signal side of the equation. The exact mechanism is still debated, but decades of research suggest it can help follicles stay in anagen longer, increase follicle size, support dermal papilla activity, and improve the environment around the hair bulb.
That explains why the new trial is so relevant. In testosterone-treated patients, sublingual minoxidil improved midfrontal hair count while the study reported no change in testosterone concentrations. Mechanistically, that is the point: support the follicle without deliberately interrupting gender-affirming hormone therapy.
Step 1: Under-the-Tongue Delivery Changes the Route Into the Body
Sublingual delivery means the medication is placed under the tongue, where the oral mucosa can absorb drug into the bloodstream. This is different from swallowing a tablet, where the drug first passes through the gut and liver before entering systemic circulation.
A recent review of topical, oral, and sublingual minoxidil described sublingual administration as a route that can bypass first-pass metabolism and may improve follicular bioavailability while limiting systemic exposure. That is a hypothesis, not a guarantee, but it is the reason sublingual dosing is being studied seriously.
The practical route comparison looks like this:
- Topical minoxidil: acts mainly through scalp application, but response can be limited by irritation, adherence, local absorption, and follicular enzyme activity.
- Oral minoxidil: is easy to take and can work systemically, but blood-pressure and fluid-retention risks require medical supervision.
- Sublingual minoxidil: aims for systemic delivery through oral mucosa, potentially with a different exposure profile from swallowed tablets.
For hair biology, the route matters because the follicle needs enough active drug signal over enough time to shift its cycle. For safety, the route matters because minoxidil is a vasodilator. Dose, absorption, peak levels, and systemic exposure are not cosmetic details.
Step 2: Minoxidil Has to Become Minoxidil Sulfate
Minoxidil is widely described as a prodrug for hair growth. The more active follicle-stimulating form is minoxidil sulfate. Research has shown that sulfotransferase activity is present in hair follicles and that inhibiting sulfotransferase can block minoxidil’s hair-growth effect while not blocking minoxidil sulfate itself.
This is one reason people respond differently to minoxidil. If the follicle environment does not convert enough minoxidil into its active sulfate form, the visible response may be weaker.
For sublingual minoxidil, this raises an important unresolved question: how much of the benefit depends on follicular sulfotransferase versus systemic conversion and delivery of active or activatable drug to the scalp? The answer may affect who responds best, what dose works, and whether sublingual treatment helps some topical non-responders.
Step 3: Dermal Papilla Cells Are Probably a Key Target
The dermal papilla is the follicle’s command center. It sits at the base of the follicle and sends signals that influence hair matrix cells, follicle size, shaft diameter, blood-vessel support, and the anagen growth phase.
Read next
Whats the best shampoo for hair loss?
A classic review concluded that the dermal papilla is probably a major site of minoxidil action. Later work supported that idea by showing minoxidil effects in cultured dermal papilla cells, including signals tied to vascular endothelial growth factor, also known as VEGF.
That matters because androgenetic alopecia is not simply hair falling out. It is follicle miniaturization. The follicle becomes less productive, anagen shortens, shaft diameter decreases, and terminal hairs can become finer intermediate or vellus-like hairs. A drug that can push dermal papilla cells toward a more growth-supportive signal may help slow or partially reverse that process.
Step 4: Potassium Channels and Adenosine May Translate the Signal
Minoxidil is an ATP-sensitive potassium-channel opener. Human hair follicles contain ATP-sensitive potassium-channel components, and lab research suggests minoxidil-sensitive channels may exist in hair follicle compartments including the dermal papilla and dermal sheath.
One important dermal papilla study found that minoxidil-induced hair-growth signaling may involve adenosine. In cultured dermal papilla cells, minoxidil increased intracellular calcium and VEGF production, and those effects were inhibited by an adenosine-receptor antagonist. That points to a chain of events where minoxidil-sensitive channel activity and adenosine signaling help dermal papilla cells produce growth-supportive messages.
In simpler terms:
- Minoxidil reaches follicle-associated cells.
- It is converted, at least partly, into minoxidil sulfate.
- Potassium-channel and adenosine-linked signaling changes dermal papilla behavior.
- Dermal papilla cells produce more growth-supportive signals such as VEGF.
- The follicle becomes more likely to remain in productive anagen growth.
This is still not the whole story. Minoxidil may also influence prostaglandin biology, Wnt/β-catenin signaling, anti-inflammatory pathways, collagen synthesis, and apoptosis resistance. But the potassium-channel/adenosine/VEGF story is one of the clearest mechanistic threads connecting minoxidil to follicle growth.
Step 5: VEGF May Improve the Follicle’s Growth Environment
VEGF is a vascular growth factor. Hair follicles are highly active mini-organs, and active growth requires oxygen, nutrients, and a supportive perifollicular blood supply. Human dermal papilla cell research found that minoxidil upregulated VEGF expression in a dose-dependent way.
That does not mean minoxidil is simply a “blood flow drug.” The old blood-flow explanation is too simplistic. But vascular support is likely part of the picture. A stronger anagen follicle needs stronger local support.
VEGF may matter because it can help:
- support perifollicular vascularization around growing follicles,
- improve the growth environment for metabolically active matrix cells,
- help sustain anagen rather than letting follicles prematurely regress,
- interact with dermal papilla signaling rather than acting as a standalone magic switch.
In testosterone-associated androgenetic alopecia, this is useful because the follicle is under androgen pressure. Minoxidil does not remove that pressure, but it may give the follicle a stronger growth push.
Why the Testosterone Result Matters Mechanistically
The new trial reported no effect on testosterone concentrations. That is exactly what a non-hormonal growth stimulant should do.
For transgender and gender-diverse patients receiving testosterone, this distinction is crucial. A treatment that improves hair growth by lowering DHT may be effective but emotionally or clinically complicated for some patients. A treatment that improves hair growth by supporting dermal papilla and anagen biology gives clinicians another pathway to discuss.
However, this does not mean sublingual minoxidil solves the androgen problem. If DHT pressure remains high in susceptible follicles, minoxidil may help growth output while miniaturization pressure continues in the background. Some patients may eventually need a combined plan: minoxidil-based growth support, scalp inflammation control, careful monitoring, and, when acceptable, an androgen-pathway discussion with a clinician.
What Is Proven, What Is Plausible, and What Is Still Unknown
What is proven: the new randomized trial reported a significant midfrontal hair-count advantage for sublingual minoxidil versus placebo at 24 weeks in testosterone-treated transgender and gender-diverse adults with mild androgenetic alopecia. The study reported no serious adverse events and no change in testosterone concentrations. Separately, minoxidil is known to require sulfation for follicle stimulation, and research supports dermal papilla, potassium-channel, adenosine, VEGF, and anagen-related mechanisms.
What is plausible: sublingual minoxidil may deliver enough minoxidil to scalp follicles to increase active minoxidil sulfate signaling, support dermal papilla growth-factor output, improve perifollicular vascular support, prolong anagen, and thicken miniaturized hairs without directly suppressing testosterone or DHT.
What is still unknown: the ideal sublingual dose, long-term cardiovascular safety, whether sublingual delivery is safer or more effective than low-dose oral minoxidil, whether follicular sulfotransferase activity predicts response, how well it works in more advanced hair loss, and whether it can maintain results for years under ongoing testosterone therapy.
Why This Mechanism Could Pair Well With Other Treatments
Sublingual minoxidil is not a full anti-miniaturization strategy by itself. It is a growth-support strategy. That means it may pair logically with treatments that target other pieces of the hair-loss puzzle.
Potential combination logic includes:
- Minoxidil: push follicles toward anagen and stronger shaft output.
- Anti-inflammatory scalp care: reduce dandruff, itching, seborrheic dermatitis, and inflammation that can worsen shedding or adherence.
- Nutrition correction: fix low ferritin, vitamin D deficiency, thyroid issues, crash dieting, or other shedding contributors when present.
- Anti-androgen discussion: consider finasteride, dutasteride, or topical anti-androgen strategies only when aligned with the patient’s goals and clinician guidance.
- Objective monitoring: track midfrontal and vertex response separately, because the new trial showed different timing by scalp region.
The important idea is that hair treatment should become more personalized. A testosterone-treated patient who wants to preserve masculinization may reasonably prioritize non-hormonal growth support first. Another patient may decide that DHT reduction is acceptable. The mechanism helps make that conversation clearer.
How You Can Use This Mechanism Today
Sublingual minoxidil should be treated as a medical option to discuss, not a kitchen experiment. Minoxidil can affect blood pressure, heart rate, fluid retention, and unwanted facial or body hair growth.
- Do not improvise sublingual minoxidil from tablets. Absorption and dose control matter, and this is not the same as a studied sublingual formulation.
- Ask whether your goal is growth support or androgen control. Minoxidil supports growth; it does not directly remove DHT pressure.
- Monitor blood pressure and side effects. Dizziness, palpitations, swelling, headaches, and unwanted hypertrichosis should be taken seriously.
- Measure frontal and vertex response separately. The controlled 24-week signal was midfrontal, while vertex improvement appeared later in the open-label extension.
- Start early if medically appropriate. Minoxidil-style treatments work best when follicles are miniaturized but still alive and producing hair.
The bottom line: sublingual minoxidil may work by giving testosterone-exposed follicles a stronger anagen-support signal without lowering testosterone. It likely depends on active minoxidil sulfate, dermal papilla potassium-channel and adenosine signaling, VEGF production, vascular support, and longer growth-phase behavior. That makes it one of the most practical non-hormonal pathways for testosterone-associated pattern hair loss, especially while larger and longer trials are still needed.
Sources
- Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil – PubMed
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations – PubMed
- Minoxidil: mechanisms of action on hair growth – PubMed
- Minoxidil sulfate is the active metabolite that stimulates hair follicles – PubMed
- Minoxidil sulfation in the hair follicle – PubMed
- Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells – PubMed
- Minoxidil upregulates vascular endothelial growth factor in human hair dermal papilla cells – PubMed
- Human hair follicles contain ATP-sensitive potassium channels sensitive to minoxidil – PubMed